Seawater requirement for the production of lipoxazolidinones by marine actinomycete strain NPS8920.
A novel marine actinomycete strain NPS8920 produces a new class of 4-oxazolidinone antibiotics lipoxazolidinone A, B and C. Lipoxazolidinone A possesses good potency (1-2 microg/mL) against drug-resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). Strain NPS8920 exhibits different morphologies in both agar and submerged cultures. The ability of strain NPS8920 to sporulate on saline-based agar media but not on deionized water-based agar medium supported that strain NPS8920 is a marine actinomycete. While strain NPS8920 does not require seawater for growth, the production of lipoxazolidinones by strain NPS8920 can only be detected in the seawater-based media. The optimal production of lipoxazolidinones was observed in the natural seawater-based medium. Strain NPS8920 produced 10-20% of lipoxazolidinones in the synthetic sea salt Instant Ocean-based medium and no production in the sodium chloride-based and deionized water-based media.
Sunga
Michelle J
MJ
Nereus Pharmaceuticals, Inc, 10480 Wateridge Circle, San Diego, CA 92121, United States.
Teisan
Sy
S
Tsueng
Ginger
G
Macherla
Venkat R
VR
Lam
Kin S
KS
D039903:Actinobacteria / Q000254:growth & development* / Q000378:metabolism*; D000900:Anti-Bacterial Agents / Q000378:metabolism*; D003470:Culture Media / Q000737:chemistry; D015394:Molecular Structure; D023303:Oxazolidinones / Q000378:metabolism*; D012623:Seawater / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D003470:Culture Media; D023303:Oxazolidinones; C524232:lipoxazolidinone A; C524233:lipoxazolidinone B; C524234:lipoxazolidinone C